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Abstract: p38 Mitogen-activated protein kinase (MAPK) plays a critical role in the activation 
of inﬂ  ammatory cells. We investigated the anti-inﬂ  ammatory effects of a p38α-selective MAPK 
inhibitor (SD-282) in a mouse transgenic (CC10:IL-13) asthma model. The CC-10-driven 
over-expression of IL-13 in the mouse lung/airway has been shown to result in a remark-
able phenotype recatitulating many features of asthma and characterized by eosinophilic and 
mononuclear inﬂ  ammation, with airway epithelial cell hypertrophy, mucus cell metaplasia, the 
hyperproduction of neutral and acidic mucus, the deposition of Charcot–Leyden-like crystal, and 
airway sub-epitheilial ﬁ  brosis. Here we show how activated p38 MAPK can be observed in the 
lungs at the onset of asthma ie, around 8 weeks of age in both female and male mice. We also 
show that administration of a p38α MAPK selective inhibitor, SD-282 at 30 or 90 mg/kg, twice 
a day for a period of four weeks beginning at the onset of asthma, signiﬁ  cantly reduced the 
inﬂ  ammation (p   0.001); hyperplasia of airway epithelium (p   0.05); goblet cell metaplasia 
and mucus hypersecretion (p   0.001) and reduced lung remodeling and ﬁ  brosis (p   0.01), 
alleviating the severity of lung damage as measured by a composite score (p   0.05). Further-
more, SD-282 signiﬁ  cantly reduced activated p38 MAPK in the lymphocytes and epithelial cells 
(p   0.001). Simultaneously, identical studies were conducted with an anti-ﬁ  brotic TGFβR1 
kinase inhibitor (SD-208) which demonstrated anti-ﬁ  brotic but not anti-inﬂ  ammatory properties. 
These ﬁ  ndings suggest that the p38α-selective MAPK inhibitor may have dual therapeutic 
potential in attenuating both the inﬂ  ammatory component and the ﬁ  brotic component of asthma 
and other Th2-polarized inﬂ  ammatory lung diseases.
Keywords: inflammation, asthma, fibrosis, p38α-selective MAPK inhibitor, SD-282, 
phosphorylated p38 MAPK, TGFβ inhibitor, SD-208, phosphorylated SMAD2/3
Introduction
In the family of mitogen-activated protein kinases (MAPK), three major enzymes have 
been well characterized, including the extracellular signal-regulated kinase (ERK or 
p42/44MAPK), the c-Jun NH2-terminated kinase, and the p38 MAPK (Sugden et al 
1998). p38 MAPK, a serine-threonine kinase, is activated in response to a variety of 
environmental stimuli, including inﬂ  ammation and cellular stress (Underwood et al 
2000). Four p38 MAPK isoforms, including α, β, δ, and γ have been characterized. 
In the human lung cDNA libraries, the levels of α and β transcripts are higher than 
those of δ and γ (Jiang et al 1997). Hence it is worth pursuing the pharmacology of an 
α-selective p38 MAPK inhibitor to keep the p38 MAPK-based drug hunt active.
IL-13 is a pleiotropic cytokine produced largely by activated CD4+ Th2 
lymphocytes. The CC10-driven over-expression of IL-13 in the lung/airway in 
CC10:IL-13 transgenic (Tg (+)) mice causes a profound phenotype reminiscent of 
asthma in humans, characterized by eosinophilic and mononuclear inﬂ  ammation, with Journal of Asthma and Allergy 2008:1 32
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mucus hyperproduction, epithelial metaplasia, subepithelial 
ﬁ  brosis, airway obstruction and AHR (Zhou et al 1999). 
The role and activity of p38 MAPK in the Tg (+) mouse 
model of asthma is not well understood.
It has been demonstrated that p38 MAPK may 
play an important role in asthma and other inﬂ  amma-
tory lung diseases. A recent study revealed that the 
p38 MAPK inhibitor SB239063 markedly reduced 
ovalbumin-induced pulmonary eosinophilia in animal 
models of asthma (Underwood et al 2000). However 
SB239063 is not selective between p38α and p38β MAPK 
isoforms. In addition, the airway eosinophilia was the 
only endpoint reported in that study. The efficacy of 
p38α-selective inhibitor SD-282 in a model of allergic 
airway remodeling and bronchial hyperresponsiveness was 
reported recently (Nath et al 2006). In the present study, 
we used p38α-selective inhibitor SD-282 and investigated 
its anti-inﬂ  ammatory effects in a mouse transgenic asthma 
model. We tested both a low dose (30 mg/kg) and a high-
dose (90 mg/kg) of SD-282. SD-282 at 90 mg/kg (twice/day, 
orally) signiﬁ  cantly reduced IL-13-induced increases in 
inﬁ  ltrating inﬂ  ammatory cells, lymphocytes, macrophages, 
p38 MAPK activation, and IL-1β expression. It also 
inhibited IL13-induced airway mucus production, epithelial 
cell hypertrophy and, intriguingly, lung ﬁ  brosis.
Historical data suggests that transforming growth 
factor-beta receptor type 1 (TGFβRI) kinase activity, but 
not p38 MAPK activation, is required for TGFβRI-induced 
ﬁ  brosis (Kapoun et al 2006). Further, TGFβRI not only 
signals through SMAD2/3 but also through MAPK. 
Interestingly, both phosphorylated, and thereby activated 
p38 MAPK and SMAD2/3, are present in Tg (+) mice. 
Therefore we also investigated the effect of TGF-β 
receptor I kinase inhibitor, SD-208 at both a low dose 
and a high-dose on lung ﬁ  brosis. SD-208 at a high-dose 
demonstrated efﬁ  cacy selectively on ﬁ  brosis in this model. 
Our ﬁ  ndings show that the use of the p38α-selective 
MAPK inhibitor, but not TGFβR1K kinase inhibitor, has 
effective dual roles in attenuating pulmonary disorders 
including inﬂ  ammation and ﬁ  brosis, and suggest that the 
p38α-selective MAPK inhibitor may have therapeutic 
potential for asthma and other inflammatory lung 
diseases.
Materials and methods
Chemical descriptions
Both p38α-selective MAPK and TGFβRI kinase inhibitors 
SD-282 and SD-208 were synthesized by the Medicinal 
Chemistry Department at Scios, Inc. Chemical structures 
and descriptions were reported in our earlier communication 
(Kapoun et al 2006).
SD-282 potency and speciﬁ  city
IC50 of SD-282 against the human p38 MAPKs (α, β, γ, 
and δ isoforms) were performed and reported in our earlier 
communication (Medicherla et al 2006 ). The IC50 values 
of SD-282 for p38α MAPK were derived from two studies. 
As reported previously (Medicherla et al 2006; Sweitzer 
et al 2004), SD-282 demonstrates 14.3-fold selectivity for 
p38α MAPK (IC50 values of 0.0016 and 0.0011 μM) com-
pared with p38β MAPK (IC50 values of 0.023 and 0.022 μM), 
whereas inhibition of p38γ MAPK and p38δ MAPK was less 
than 50%, even at concentrations of 10 μM. When tested in 
vitro at a concentration of 10 μM, SD-282 demonstrated no 
inhibitory activity against a panel of other kinases, including 
extracellular signal-regulated kinase 2, c-Jun NH2-terminal 
kinase-1, and mitogen-activated protein kinase-activated 
protein kinase-2. In addition, SD-282 demonstrates no effect 
on the activity of puriﬁ  ed COX-1 or COX-2 enzymes.
Pharmacokinetics studies in IL-13 mice revealed that 
SD-282 and SD-208 at 90 mg/kg reached peak levels 30 min 
after their administration, and their trough levels at that 
dose are trace amounts at 8 h. Hence, mice in the studies 
reported here were treated twice daily by oral gavage with 
SD-282 and SD-208.
Animals
CC10:IL-13 transgenic mice, used as Tg (+), were provided 
by Dr Jack A Elias (Yale University of Medicine) and wild 
type mice were provided by Charles River Laboratories, 
San Diego, CA. The techniques for identifying transgenic 
mice were obtained from Dr Elias’s Laboratories (Tang et al 
1996; Pack et al 1981; Ray et al 1997). Transgenic mice were 
generated in (CBA × C57BL/6) F2 eggs using a standard 
pronuclear injection as described previously (Ray et al 1997; 
Hogan et al 1986). The presence or absence of the transgene 
in the resulting mice and their progeny was determined using 
tail DNA and Southern blot analysis with 32P-labeled murine 
IL-13 cDNA as a probe or PCR. When PCR was used, 
primers were used to span the IL-13–hGH junction that was 
unique to the transgene. The primers were: 5’-CAA AAC 
TGC TCA GCT ACA CAA AG-3’ and 5’-GAG CTG TTT 
GTT TTT CTC TCT CC-3’. The following PCR protocol 
was used: 95 °C for 8 min; 35 cycles of 95 °C for 1 min, 
56 °C for 1 min, and 72 °C for 1 min, and a ﬁ  nal extension 
at 72 °C for 10 min (Zhou et al 1999).Journal of Asthma and Allergy 2008:1 33
p38 MAPK inhibition ameliorates lung inﬂ  ammation and f ibrosis
Measurement of activated p38 MAPK 
in the lungs of CC10:IL-13 transgenic 
Tg (+) mice
Animal experimental protocols were approved by the 
Preclinical Ethical Committee of Charles River, San Diego, 
US. Phosphorylated p38 MAPK was measured in both 
male and female mice at time intervals including 4, 8, 
and 12 weeks. Three mice per time point were taken for 
histochemical analysis of posphorylated p38 MAPK and 
phosphorylated SMAD2/3. Details for immunohistochem-
istry are provided in a later section.
Experimental design
Grouping was randomized and animals were divided into 
seven groups. In each group were ten mice (5 females 
and 5 males). Baseline Tg (+) mice were sacrificed at 
8 weeks (±3days) of age (n = 8). At the age of 8 weeks treat-
ment was initiated in remaining groups (n = 10). Mice were 
administered p38α-selective MAPK inihbitor SD-282 via 
gastric gavage at doses of 30 (low dose) and 90 mg/kg (high-
dose) respectively, twice daily for 4 weeks, or TGFbetaRI 
inhibitor SD-208 at 20 (low dose) and 60 mg/kg (high-dose) 
twice daily, or 1% methyl cellulose vehicle. Tg (+) mice in 
the test compound or vehicle-treated groups were sacriﬁ  ced 
at the age of 12 weeks. Wild type mice without treatment 
were sacriﬁ  ced at 12 weeks and used as Tg (−) naïve.
Histology, immunohistochemistry, 
and morphometry
Left lungs were inﬂ  ated with 10% buffered formalin and 
ﬁ  xed in the same ﬁ  xative for 48 hours. Three equal slabs 
from each left lung were segmented transversely so that 
the ﬁ  rst generation of bronchus (segmental bronchus) was 
obtained in cross section, and samples were processed and 
parafﬁ  n embedded. Serial sections were cut at 5 μm thickness 
and stained with hematoxylin and eosin (H&E), periodic 
acid-schiff and hematoxylin (PASH), Alcin blue or Masson’s 
trichrome stains.
For immunohistochemical (IHC) staining, slides were 
deparafﬁ  nized and hydrated in PBS followed by blocking 
the endogenous peroxide with 3% hydrogen peroxide. To 
avoid nonspeciﬁ  c reaction with the primary antibody, slides 
were pretreated with 10% normal donkey serum before 
incubation with the primary antibody produced in goat, with 
10% normal goat serum before incubation with primary 
antibody produced in rat and rabbit. The primary antibodies 
used in this study were goat anti-CD3 at concentration 
of 1:100 (Santa Cruz Biotechnology, Inc. Cat. No. sc-1127), 
goat anti-mouse IL-1β at concentration of 1:100 (R&D 
System, Cat. No. AF-401-NA), rat anti-mouse F4/80 at 
concentration of 1:25 (Novus Biological, Cat. No. AB 
6640–250), rabbit anti-phospho-p38 MAPK (Thr180/
Tyr182) at concentration of 1:50 (Cell Signaling, Cat. 
No. 4634), rabbit anti-phospho-SMAD2/3 at concentration 
of 1:5000. (Cell Signaling, Cat. No. 3101L). Normal goat 
IgG, normal rat IgG, and normal rabbit IgG were used as 
negative controls for the primary antibody produced in 
goat, rat, and rabbit respectively. Donkey anti-goat biotin-
lated IgG (Chemicon International, Inc. Cat. No. AP180B) 
for CD3 and IL-1β, goat anti-rat biotinlated IgG (Chemicon 
International, Inc. Cat. No. AP183B) for F4/80, and goat 
anti-rabbit biotinlated IgG (Chemicon International, Inc. 
Cat. No. AP187B) for p38 MAPK and SMAD2/3 were 
used as secondary antibodies. The immunoreactivities 
were visualized by ABC reagents (Vector, Burlingame, 
Cat. No. PK-6100) and diaminobenzidine (Research 
Genetic, Cat. No. 750118) followed by counterstaining 
with hematoxylin.
Histological and morphometric analysis
The development of asthma based on histological parameters 
(Hogan et al 1986; Gupta et al 1998; Zhou et al 1999) was 
evaluated quantitatively following H&E stain to demonstrate 
the presence of inﬂ  ammation, PASH stain to demonstrate 
the bronchial epithelium, and mucin within goblet cell and 
trichrome stain to demonstrate the muscular layer and the 
presence of extracellular matrix. The histological parameters 
presented included inﬂ  ammation and crystal formation, 
hyperplasia of bronchial epithelium, goblet cell metaplasia 
and mucus hypersecretion, smooth muscle hypertrophy 
and hyperplasia, subepithelial ﬁ  brosis in airway wall, and 
ﬁ  brosis of lung parenchyma. Morphometric (Image) analy-
sis was performed using a Nikon E800 light microscope 
equipped with Q Imaging digital camera. Image Pro Plus 
4.5 software (Media Cybernetics, Silver Spring, MD) was 
used for quantitative measurements. The total area of lungs 
from the three slabs of left lung and inﬂ  amed lung area 
were measured. The percentage of inﬂ  amed lung area was 
then calculated, to evaluate inﬂ  ammation. The inﬂ  amed 
area was deﬁ  ned as different inﬂ  ammatory cell inﬁ  ltra-
tion and the deposition of Charcot–Leyden-like crystal. 
The inﬂ  ammatory cells included eosinophils, neutrophils, 
macrophages, plasma cells, and lymphocytes. The area was 
measured manually using the area measurement feature of 
Image Pro Plus 4.5 software. Both total area and inﬂ  amed Journal of Asthma and Allergy 2008:1 34
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area were measured throughout the lung section. Sections 
stained with H&E were used to measure inflammation 
under a 10x lens. The thickness of epithelial cells in the 
segmental bronchus was measured, to evaluate hyperplasia 
of the bronchial epithelium. The thickness of the epithelium 
was measured by the height (Figure 3b, marked by I), a line 
drawn perpendicular to the basal lamina underlying the 
surface of epithelium. The height of the epithelium from 
four zones of segmental bronchus, at 12, 3, 6, and 9 o’clock 
(Figure 4b–C) per section was measured using the length 
measurement feature of Image Pro Plus 4.5 software. The 
average height from the four zones was calculated. Sections 
stained with PASH were used to measure the thickness of the 
epithelium under a 40x lens. The thickness of the muscular 
layer in the segmental bronchus was measured, to evaluate 
muscle hypertrophy and hyperplasia. The thickness of the 
muscular layer was measured by the height, a line drawn 
perpendicular to the basement membrane underlying the 
muscular layer. The height of the muscular layer from four 
zones of segmental bronchus, at 12, 3, 6, and 9 o’clock 
(Figure 5c–A) per section was measured using the length 
measurement feature of Image Pro Plus 4.5 software. The 
average height from the four zones was calculated. Sections 
stained with Masson’s trichrome were used to measure the 
thickness of the muscular layer under a 40x lens. The percent-
age of mucin-secreted goblet cells in the segmental bronchus 
was counted to evaluate the goblet cell metaplasia and mucus 
hypersecretion. Total epithelial cells and PASH-stained 
mucin-positive goblet cells in the segmental bronchus were 
counted manually under a 40x lens. The percentage of mucin-
secreted goblet cells was then calculated. The thickness of 
basement membrane was measured to evaluate subepithelial 
ﬁ  brosis, and the total area (mm2) of collagen deposition per 
section was measured to evaluate lung ﬁ  brosis. The thick-
ness of basement membrane measurement was similar to the 
measurement of the muscular layer. The total areas (mm2) of 
collagen deposition per section were measured using Image 
Pro Plus 4.5 software. Collagens stained (with Masson’s 
trichrome) in blue were chosen as the area of interest, and 
the threshold was set up to select the blue area. The total 
number of blue areas per section under 10x were selected 
and measured. Then the total collagen depositions were 
calculated to evaluate lung ﬁ  brosis.
The severity of the lung damage was obtained from the 
total scores of histological parameters. Scores were obtained 
from the qualitative analysis of each parameter deﬁ  ned as 
normal = 0, mild = 1, moderate = 2, severe = 3, and very 
severe = 4.
Immunohistochemical and morphometric 
analysis
Phospho-p38 MAPK and IL-1β IHC staining was analyzed 
qualitatively for the presence of positive labeling and 
the intensity of staining on a score of 0 to 4, none = 0, 
mild = 1, moderate = 2, strong = 3, and strongest = 4. For CD3 
and F4/80 IHC, the CD3 positively labeled T-lymphocytes 
and F4/80 positively labeled macrophages in 10 independent 
hot ﬁ  elds under a magniﬁ  cation of 400 (40 × lens) were each 
counted. P-SMAD2/3 staining was analyzed quantitatively 
by: the percentage of positively labeled epithelial cells in the 
airway wall; the percentage of positively labeled proliferate 
alveolar epithelial cells (type-2); macrophages and ﬁ  broblasts 
in the lung parenchyma in 10 independent hot ﬁ  elds under a 
magniﬁ  cation of 400 (40× lens).
Statistical analysis
Data were analyzed by one-way ANOVA followed by the 
Bonferroni multiple group comparison test. A p value   0.05 
was accepted as statistically signiﬁ  cant.
Results
First, presence and the temporal and spatial pattern of 
activation of p38α MAPK and of TGFβRIK were determined 
in the CC10:IL-13 tg lung. Next, the effects of p38 MAPK 
and TGFbRIK inhibition on the development of asthma 
were evaluated by measuring the different histological 
parameters and the severity of lung damage. SD-282 at 90 
mg/kg, BID for 4 weeks did not cause any weight loss or 
animal deaths.
Phosphorylated p38 MAPK and SMAD2/3 
levels in the Tg (+) lung
Both p38 MAPK and SMAD2/3 were phosphorylated, 
indicating activation, in Tg (+) lung but the cellular pattern 
of these two effectors differed. Phospho-p38 (p-p38) MAPK 
was found in bronchial and bronchiolar epithelial cells and 
inﬁ  ltrated lymphocytes (Figure 1a). A strong intensity of 
p-p38 MAPK staining was found in both 8- and 12-week-old 
Tg (+) mice. Mild intensity of p-p38 MAPK staining was 
found in 16 week-old Tg (+) mice. No p-p38 MAPK activa-
tion was found in either 8- or 12-week-old Tg (−) mice.
Phospho-SMAD2/3 (p-SMAD2/3) activation was found 
in epithelial cells in airway (Figure 1b) and lung parenchyma 
(Figure 1c) such as alveolar epithelial cells (mostly type 2), 
ﬁ  broblasts, and macrophages. p-SMAD2/3 activation was 
found in 29% of epithelial cells in the airway with moderate Journal of Asthma and Allergy 2008:1 35
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Figure 1 p38 MAPK and SMAD 2/3 phosphorylation in lungs of CC10:IL-13 transgenic mice during development of asthma-like phenotype (8–16 weeks of age). The noted 
values represent the MEAN±SD, n = 3. [a] Score of p-p38 MAPK (IHC) activation in the epithelial cells of airway and inﬁ  ltrated lymphocytes. [b] Percentage of p-SMAD2/3 
(IHC) positively labeled epithelial cells in the airway. [c] Percentage of p-SMAD2/3 (IHC) positively labeled lung parenchyma cells.Journal of Asthma and Allergy 2008:1 36
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intensity and 13% in lung parenchyma in 8-week-old Tg (+) 
mice. p-SMAD2/3 activation was found in 38% of epithe-
lial cells in the airway with moderate intensity and 19% in 
lung parenchyma in 12-week-old Tg (+) mice. p-SMAD2/3 
activation was found in more than 40% of epithelial cells 
in the airway with strongest intensity, and 11% in the lung 
parenchyma in 16-week-old Tg (+) mice. No p-SMAD2/3 
activation was found in any of the cells in either 8 or 
12-week-old Tg (−) mice.
SD-282 reduces inﬂ  ammation, edema, 
and crystal formation in the lungs
In the Tg (+) vehicle-treated mice, the lungs were enlarged 
(edema) and consolidated. Alveoli, small airways, and 
large airways were filled with lymphocytes, eosinophils, 
neutrophils, and prominent numbers of enlarged macrophages 
which contained granular and crystalline intracellular materials 
(Figure 2a, 2b, and 2c). Alveoli and small and large airways were 
ﬁ  lled with Charcot–Leyden-like crystals (Hogan et al 1986); that 
is, long, thin, rectangular and needlelike crystals composed of 
amorphous proteinaceous material. These histological changes 
were mild in the mice in the Tg (+) baseline group. In the Tg 
(+) SD-282 high-dose group, the lungs were observed to be less 
consolidated, and alveoli and airways were ﬁ  lled with fewer 
eosinophils, lymphocytes, macrophages, and crystals. The total 
inﬂ  amed left lung area was 24.29 ± 16.88 mm2 in the baseline 
group and 60.39 ± 12.56 mm2 in the vehicle-treated group. In 
the SD-282 high-dose treated group, the inﬂ  amed left lung area 
was 38.84 ± 10.73 mm2 and reduced 36% compared with the 
Tg (+) vehicle group (p   0.05). Treatment with SD-282 at a 
Figure 2 Effect of SD-282 on inﬂ  ammation induced in the CC10:IL-13 transgenic asthma model analyzed following H&E stain. [a] SD-282 at high-dose signiﬁ  cantly reduces the 
inﬂ  ammation (p   0.05). The noted values represent the MEAN ± SD on a minimum of eight animals. [b] SD-282 reduces the inﬂ  ammatory response. H&E, x40 showing lung 
sections from Tg (−) naïve (A), Tg (+) baseline (B), Tg (+) vehicle (C) and Tg (+) SD-282H (D). C showing lungs extremely enlarged and consolidated; alveoli, small and large 
airway ﬁ  lled with inﬂ  ammatory cells in the Tg (+) mice treated with vehicle as compared with mild inﬂ  ammatory response at onset of the asthma (B). D showing lung with 
less inﬂ  ammatory response in SD-282 high-dose treated Tg (+) mice. [c] SD-282 reduces crystal formation and prevents eosinophil, lymphocyte, and macrophage inﬁ  ltration. 
H&E, x400 showing lung sections from Tg (+) baseline (A), Tg (+) vehicle (B and C) and Tg (+) SD-282H (D). Mild inﬂ  ammatory cell inﬁ  ltration is seen at onset of the asthma/
baseline (A). Long, thin, rectangular, and needle-like crystals (thin arrow), stained with eosin are seen in the vehicle-treated Tg (+) mice (B). Collections of lymphocytes (arrow), 
eosinophils (arrowhead), and enlarged macrophages (thin arrow) are seen in the vehicle-treated Tg (+) mice (C). Reduced crystal formation and fewer eosinophil, lymphocyte, 
and macrophage are seen in the SD-282 high-dose treated Tg (+) mice (D).
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low dose showed a trend toward reducing the inﬂ  ammation but 
the difference was not signiﬁ  cant.
SD-282 reduces hyperplasia of epithelial 
cell in airway wall
In the Tg (+) baseline group, obvious hyperplasia of bronchial 
and bronchiolar epithelial cells was observed, with cells 
being taller and wider compared with the Tg (−) naïve group 
(Figure 3a and 3b). The thickness of epithelial cells in the 
segmental bronchus was 0.026 ± 0.004 mm in the baseline 
group vs 0.016 ± 0.004 mm in the naïve group. In the Tg (+) 
vehicle-treated group, severe hyperplasia of bronchial and 
bronchiolar epithelial cells was observed; the thickness of 
epithelial cells was 0.028 ± 0.004 mm. In the Tg (+) SD-282 
high-dose treated group, the thickness of epithelial cells was 
0.022 ± 0.003 mm and was reduced to 21% compared with 
the Tg (+) vehicle group (p   0.05). No improvement of 
hyperplasia of bronchial and bronchiolar epithelial cells was 
observed in the SD-282 low-dose group.
SD-282 reduces goblet cell metaplasia 
and mucus hypersecretion
In normal mice, goblet cells typically comprise less than 
20% of cells in the bronchial epithelium, and goblet cell 
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Figure 3 Effect of SD-282 on the hyperplasia of airway wall epithelial cells induced in the CC10:IL-13 transgenic asthma model and analyzed following PASH stain. [a] SD-282 
at a high-dose signiﬁ  cantly reduces the thickness of epithelial cells (p   0.05). The noted values represent the MEAN ± SD on a minimum of eight animals. [b] PASH staining of 
lung sections, x400 from Tg (−) naïve (A), Tg (+) baseline (B), Tg (+) vehicle(C), and Tg (+) SD-282H (D). Increased thickness of epithelial cells is seen in both baseline (B) and 
vehicle-treated Tg (+) mice (C) compared with Tg (−) mice (A), and decreased thickness of epithelial cells is seen in the SD-282 high-dose treated Tg (+) mice (D).Journal of Asthma and Allergy 2008:1 38
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numbers were greatly diminished in the segmental bronchus 
(Figure 4a, 4b, and 4c). In Tg (+) mice we observed an 
increased number of goblet cells in the segmental bronchus, 
and prominent mucus production by airway epithelium in 
both Tg (+) baseline and Tg (+) vehicle groups. Both neutral 
(PAS positive) and acidic (Alcin blue positive) mucus were 
identiﬁ  ed (Figure 4b). In the Tg (+) SD-282 high-dose treated 
group, goblet cell metaplasia and mucin hypersecretion were 
dramatically inhibited. The percentage of mucin-secreted 
goblet cells in the segmental bronchus was 22.8% ± 12.11% 
vs 50% ± 5.8% in the Tg (+) vehicle group, and was reduced 
by 44% (p   0.001). The inhibition of goblet cell metaplasia 
and mucus hypersecretion was not observed in the SD-282 
low-dose group.
SD-282 reduces subepithelial ﬁ  brosis 
in airway wall
Measurement of thickness of the basement membrane 
revealed ‘thickening’ in the membrane (Figure 5a, 5b, 
and 5c). The ‘thickening’ was the result of a dense ﬁ  brotic 
response characterized by enhanced accumulation of 
collagens. We observed very mild collagen deposition 
around the basement membrane in the Tg (+) baseline group. 
Enhanced accumulation of collagen was observed in the Tg 
(+) vehicle group. Signiﬁ  cantly less thickening in the base-
ment membrane and subepithelial ﬁ  brosis was observed in 
the SD-282 high-dose group (p   0.05). SD-282 at low dose 
had no effect on thickening in the basement membrane.
SD-282 reduces ﬁ  brosis of lung 
parenchyma
There was mild remodeling at 8 weeks and obvious organiza-
tion and remodeling at 12 weeks in the Tg (+) compared to 
vehicle-treated groups (Figure 5b and 5c). Fibrotic beads with 
elongated ﬁ  broblasts and collagen deposition in the alveolar 
walls and within the alveoli were observed in the treated 
groups. The ﬁ  brotic changes were very mild in the Tg (+) 
baseline group. The ﬁ  brosis was reduced to 54% in the Tg (+) 
SD-282 high-dose group (p   0.01).
SD-282 alleviates the severity of asthma
An integrated evaluation of severity of asthma-like 
histological changes was obtained from the total scores 
of six histological parameters. The severity of asthma in 
the transgenic model was signiﬁ  cantly reduced to 42% in 
the Tg (+) SD-282 high-dose group (p   0.05, data not 
shown).
SD-282 reduces p-p38 MAPK in the lungs
p-p38 MAPK activation was found in bronchial and 
bronchiolar epithelial cells and inﬁ  ltrated lymphocytes in the 
Tg (+) baseline group (Table 1 and Figure 6-1). Enhanced 
p-p38 MAPK activation was found in Tg (+) vehicle-treated 
groups. p-p38 activation was found in only one animal in 
the Tg (+) SD- 282 high-dose group and the activation was 
inhibited by 25 fold (p   0.001). No p-p38 MAPK activation 
was found in the Tg (−) naïve group.
SD-282 reduces IL-1β in the lungs
IL-1β expression was found in the inﬂ  ammatory PMN cells in 
the lung in the Tg (+) baseline group and enhanced expression 
of IL-1β was found in the Tg (+) vehicle group (Table 1 and 
Figure 6-2). The expression was reduced by 3.9-fold in the 
Tg (+) SD-282 high-dose group (p   0.05).
SD-282 reduces CD3 in the lungs
CD3-positive T lymphocytes, a hallmark and F4/80 positive 
macrophages numbers, were markedly increased in number 
in the Tg (+) vehicle-treated group. Both were markedly 
decreased in number (p   0.05 and p   0.01, respectively) 
in the Tg (+) SD-282 high-dose treated group (Table 1 and 
Figure 6-3) and F4/8 IHC (Table 1 and Figure 6-4).
SD-208 reduces ﬁ  brosis
Unlike p38 MAPK inhibitor SD-282, TGFβRIK inhibitor 
SD-208 reduced ﬁ  brosis selectively, with no signiﬁ  cant effect 
on lung inﬂ  ammation. The anti-ﬁ  brotic effect is consistent 
with reduced levels of p-SMAD2/3 (Table 2).
Discussion
IL-13 is a critical cytokine produced largely by acti-
vated CD4+ Th2 lymphocytes. Th2-dominated inflam-
mation is a cornerstone of the asthmatic diathesis. 
The targeted pulmonary expression of IL-13 causes 
human-like asthma which is characterized by the presence 
of severe inﬂ  ammation, edema, and crystal formation in 
the lung; severe hyperplasia of bronchial and bronchio-
lar epithelium; marked goblet cell metaplasia and mucus 
hypersecretion; and moderate ﬁ  brosis of airway and lung 
parenchyma. The CC10-driven overexpression of IL-13 
transgenic modeling has also proved to be a powerful method 
for deﬁ  ning and comparing the in vivo effector functions in 
asthma-relevant molecules. We used a potent and highly 
selective p38α-selective MAPK2 inhibitor, which inhibits 
kinase activity of the p38 MAPK isoform, to probe the role of 
p38 MAPK in a CC10:IL-13-driven mouse model of asthma. Journal of Asthma and Allergy 2008:1 39
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Figure 4 Effect of SD-282 on goblet cell metaplasia and mucus hypersecretion induced in the CC10:IL-13 transgenic asthma model, analyzed after PASH stain. [a] SD-282 at a 
high-dose signiﬁ  cantly inhibited the goblet cell metaplasia and mucus hypersecretion (p   0.001). The noted values represent the MEAN ± SD on a minimum of eight animals. 
[b] Neutral and acidic mucus are overproduced in goblet cells of segmental bronchus. PASH and Alcian blue stain, x200 showing lung sections from Tg (−) naïve (A&B) and 
Tg (+) baseline (C&D). PASH showing the red-purple cytoplasmic inclusion (neutral mucus) and Alcian blue showing the blue cytoplasmic inclusion (acid mucus). There is almost 
no neutral and acid mucus production in the epithelial cell in Tg (−) mice (A&B). In contrast, there is hypersecretion of both neutral and acid mucus from goblet cells in Tg (+) 
mice from baseline (C&D). [c] PASH, x200 (in green box) and x400 showing lung sections from Tg (−) naïve (A), Tg (+) baseline (B), Tg (+) vehicle (C) and Tg (+) SD-282H 
(D). Mucus overproduction and goblet cell metaplasia are seen in both baseline (B) and vehicle-treated Tg (+) mice (C) compared with Tg (−) mice (A), and decreased mucus 
production and fewer goblet cells are seen in the SD-282 high-dose treated Tg (+) mice (D).Journal of Asthma and Allergy 2008:1 40
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Table 1 Effect of SD-282 on p38 MAPK activation in the airway epithelial cells and inﬁ  ltrated lymphocytes (analyzed after p-p38 MAPK IHC staining); 
on IL-1β expression in the inﬂ  ammatory PMN cells (analyzed after IL-1β IHC staining); on number of inﬁ  ltrated CD3+ T-lymphocytes (analyzed 
after CD3 IHC staining), and on activated macrophages in the parenchyma of the lung (analyzed after F4/80 IHC staining) in the CC10:IL13 
transgenic mouse asthma model. SD-282 at a high-dose signiﬁ  cantly inhibits the level of phosphorylated p38 MAPK in the epithelial cells of 
airway and inﬁ  ltrated lymphocytes compared with the vehicle-treated group (p   0.001). SD-282 at a high-dose signiﬁ  cantly inhibits IL-1β 
expression compared with the vehicle-treated group (p   0.05). SD-282 at a high-dose signiﬁ  cantly decreases the number of CD3+T-lympho-
cytes compared with the vehicle-treated group (p   0.05). SD-282 at a high-dose signiﬁ  cantly decreases the number of activated macrophages 
in the parenchyma of the lung compared with the vehicle group (p   0.001). The noted values represent the MEAN ± SD on a minimum of 
eight animals. *Values represent scores on the intensity of the IHC staining and #values represent the number of IHC positively labeled cells
Genotype Treatment *p-p38 MAPK *IL-1β
#CD3 #F4/80
Tg (−) naive 0 ± 00  ± 0 64 ± 17 29 ± 8
Tg (+) baseline 2.13 ± 0.99 1.5 ± 0.53 142 ± 54 110 ± 29
Tg (+) vehicle 3.3 ± 0.67 2.6 ± 1.07 382 ± 210 183 ± 42
Tg (+) SD-282 0.13 ± 0.35 0.75 ± 1.04 196 ± 117 92 ± 18
p value p   0.001 p   0.05 p   0.05 p   0.001
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Figure 5 Effect of SD-282 on ﬁ  brosis induced in the CC10:IL-13 transgenic asthma model analyzed after Masson’s trichrome stain. [a] SD-282 at high-dose signiﬁ  cantly reduces 
ﬁ  brosis of lung parenchyma compared with the vehicle-treated group (p   0.01). The noted values represent the MEAN ± SD on a minimum of eight animals. [b] Thickness of base-
ment membrane following Masson’s trichrome stain. SD-282 at high-dose signiﬁ  cantly reduces subepithelial ﬁ  brosis compared with the vehicle-treated group (p   0.05). The noted 
values represent the MEAN ± SD on a minimum of eight animals. [c] Masson’s trichrome stain, x200 showing lung sections from Tg (+) baseline (A), Tg (+) vehicle (B) and Tg (+) 
SD-282H (C). Very mild collagen deposition stained in blue (black arrow) around the basement is seen in Tg (+) mice in baseline (A). Enhanced accumulation of collagen stained in 
blue (black arrow) is seen in the vehicle-treated Tg (+) mice (B). Less collagen accumulation and reduced thickening in the basement membrane (black arrow) are seen in the SD-
282 high-dose treated Tg (+) mice (C). Masson’s trichrome stain, x100 and x400 (in large green box with arrow) showing lung sections from Tg (+) baseline (D), Tg (+) vehicle (E), 
and Tg (+) SD-282H (F). Mild ﬁ  brotic change is seen in the Tg (+) mice in baseline (D). Numerous ﬁ  brotic beads with collagen deposition stained in blue (green box) and elongated 
ﬁ  broblasts are seen in the vehicle-treated Tg (+) mice (E). Reduced ﬁ  brotic beads are seen in SD-282 high-dose treated Tg (+) mice (F).Journal of Asthma and Allergy 2008:1 41
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Figure 6 Effect of p38 MAPK inhibition on immune cell inﬁ  ltration and activation in CC10:IL-13 mice [1] p-p38 MAPK IHC stain, x400 showing no p-p38 MAPK activation 
in Tg (−) mice (1-A), enhanced p-p38 MAPK activation in the epithelial cells of airway (1-B) and inﬁ  ltrated lymphocytes(1-C) in the vehicle-treated Tg (+) mice and com-
pleted inhibition of p-p38 MAPK activation in the epithelial cells in the SD-282 high-dose treated Tg (+) mice (1-D). [2] IL-1β IHC stain, x400 showing no IL-1β expression 
in Tg (−) mice (2-A), mild IL-1β expression in the PMN cells in Tg (+) mice in baseline (2-B), increased IL-1β expression in the vehicle-treated Tg (+) mice (2-C) and less 
IL-1β expression in the PMN cells in the SD-282 high-dose treated Tg (+) mice (2-D). [3] CD3 IHC stain, x400 showing few CD3+T-lymphocytes in the lung of Tg (−) 
mice (3-A), mild CD3+ T-lymphocyte inﬁ  ltration in the lung of Tg (+) mice in baseline (3-B), markedly increased number of CD3+ T-lymphocyte in the lung of Tg (+) mice 
treated with vehicle (3-C) and signiﬁ  cantly decreased number of CD3+ T-lymphocytes in the lung of Tg (+) mice treated with the high-dose of SD-282 (3-D). [4] F4/80 
IHC, x400 showing no activated macrophages in the lung of Tg (−) mice (4-A), few activated macrophages in the lung of Tg (+) mice in baseline (4-B), markedly increased 
number of activated macrophages in the lung of Tg (+) mice treated with vehicle (4-C), and decreased number of activated macrophages in the lung of Tg (+) mice treated 
with high-dose of SD-282 (4-D).
Our present ﬁ  ndings reveal that p38 MAPK phosphorylation, 
shown IHC assay in the lung tissue of transgenic mice, was 
signiﬁ  cantly higher compared with non-transgenic naïve 
mice. SD-282 at high-dose (90 mg/kg twice daily) produces 
inhibition of the p38 MAPK activation in the epithelial 
cells of the airway and in the inﬁ  ltrating lymphocytes, and 
attenuates IL-13-induced pulmonary inﬂ  ammation, release 
of Th2 cytokines into the airway, airway mucus production, 
hyperplasia of airway epithelium and lung ﬁ  brosis. This 
ﬁ  nding proves that p38 MAPK plays an important roll in 
CC10: IL-13 asthma.
Our data show that the p38α-selective MAPK inhibitor 
signiﬁ  cantly reduces the number of CD3+ T-cells and 
macrophages in the lung. There is now clear evidence 
that Th2 cells play an essential role in the pathogenesis 
of asthmatic airway inﬂ  ammation (Herrick et al 2003; 
Larche et al 2002). Th2 cytokines can be produced by 
various resident cells, including bronchial epithelial 
cells, tissue mast cells, and alveolar macrophages, and 
by inﬁ  ltrating inﬂ  ammatory cells, such as lymphocytes 
and eosinophils. The p38 MAPK signaling pathway has 
been shown to be involved in cytokine production from Journal of Asthma and Allergy 2008:1 42
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a variety of cell types. TCR engagement and/or CD28 
co-stimulation of CD4+ T cells has been shown to induce 
IL-4 and IL-13 production and Th2 cell differentiation via 
activation of p38 MAPK (Schafer et al 1999; Skapenko 
et al 2001; Lu et al 2004).
Eosinophils, lymphocytes, and macrophages are believed 
to be the principal effector cells for the pathogenesis of 
inﬂ  ammation of asthma. Our present ﬁ  ndings show that 
the administration of the p38α-selective MAPK inhibitor 
prevents eosinophil and lymphocytes inﬁ  ltration into the 
airways and reduces the number of macrophages. Similarly, 
IHC assay also conﬁ  rmed that the p38α-selective MAPK 
inhibitor reduces the number of CD3+ T-lymphocytes and 
F4/80 macrophages. Eosinophil transmigration into the air-
ways is a multi-step process, orchestrated by Th2 cytokines 
such as IL-4, IL-5, and IL-13, and coordinated by speciﬁ  c 
chemokines in combination with adhesion molecules, such 
as vascular cell adhesion molecule-1 (VCAM-1) and very 
late antigen-4 (VLA-4) (Lukacs et al 2001; Koo et al 2003). 
IL-13 has been shown to be by far the most potent inducer of 
eotaxin expression by airway epithelial cells (Li et al 1999). 
Furthermore, the p38 MAPK pathway has been shown to 
be involved in the intrinsic mechanism of eotaxin-induced 
eosinophil cytoskeletal rearrangements, chemotaxis, and 
degranulation (Kampen et al 2000); together the observed 
reduction in airway eosinophilia by the p38α-selective 
MAPK inhibitor is likely a result of reduction in Th2 
cytokine production, leading to downregulation of chemo-
kine production and eosinophil chemotaxis.
Our ﬁ  ndings demonstrate a dramatic reduction in mucus 
production with less goblet cell hyperplasia in the Tg (+) 
SD-282 high-dose treated group compared with the Tg 
(+) vehicle-treated group. Studies using undifferentiated 
tracheobronchial epithelial cells showed that Th2 cells and 
cytokines ( Zhu et al 1999; Justice et al 2002) are linked 
to mucus hypersecretion by their effects on mucin gene 
expression in the airway epithelium. In addition, a recent 
study showed that IL-13-induced goblet cell hyperplasia, 
and mucin MUC5AC protein expression in human bronchial 
epithelial cell cultures, were mediated by the p38 MAPK 
signaling pathway and could be inhibited by a p38 inhibitor 
(Atherton et al 2003). Therefore, the observed decrease in 
mucus production in the p38α-selective MAPK inhibitor 
treated group may be attributed to the substantial drop in 
Th2 cytokines in asthmatic mice treated with vehicle and/
or downregulation of p38α-selective MAPK in the IL-13 
responsive airway epithelium.
It is well-established that p38 MAPK regulates key 
pro-inﬂ  ammatory molecules in inﬂ  ammatory cells (Schafer 
et al 1999; Nath et al 2006). Our ﬁ  ndings demonstrate that 
IL-1β expression was signiﬁ  cantly inhibited by SD-282 in 
inﬂ  ammatory PMN cells. The down regulation of IL-1β by 
SD-282 supports inhibition of p-38 related IL-1β release 
from the inﬂ  ammatory cells.
The stimuli that induce airway remodeling are not well 
deﬁ  ned. This is compounded by the complex relationship 
between inﬂ  ammation and remodeling, with chronic inﬂ  am-
mation inducing remodeling responses in some settings. 
The relationship between inﬂ  ammation and remodeling 
gains support from the results reported here. We observed 
mild ﬁ  brosis in the early stage and severe ﬁ  brosis in the late 
stage of asthma development in mice. Our ﬁ  nding demon-
strate that ﬁ  brosis was signiﬁ  cantly reduced in the Tg (+) 
SD-282 high-dose treated group compared with the Tg (+) 
vehicle-treated group. The MAPK and TGFβR1/SMAD2/3 
signaling pathways play critical roles in inﬂ  ammation and 
ﬁ  brogenesis, respectively (Li et al 2006). It is very well 
established that the MAPK pathway is responsive to TGFβR1 
stimulation and coordinates with SMAD2/3 signaling in 
many inﬂ  ammatory and ﬁ  brotic disease states (Kapoun et al 
2006; Dziembowska et al 2007; Martin et al 2007). Inﬂ  am-
mation and ﬁ  brogenesis are the two determinants of the 
Table 2 Effect of TGFβRI kinase inhibitor, SD-208 and p38α-selective MAPK inhibitor, SD-282 both at a high-dose signiﬁ  cantly reduce 
ﬁ  brosis of lung parenchyma compared with the vehicle-treated group (p   0.05 and p   0.01).   The noted values represent the MEAN ± SD 
on a minimum of eight animals
Genotype Treatment Fibrosis of lung parenchyma mm2/per section p value
Tg (−) naive 0 ± 0
Tg (+) baseline 0.00098 ± 0.00059
Tg (+) vehicle 0.02631 ± 0.01210
Tg (+) SD-208 0.01629 ± 0.0038 p   0.05
Tg (+) SD-282 0.01213 ± 0.0077 p   0.01Journal of Asthma and Allergy 2008:1 43
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progression of lung ﬁ  brosis, the common pathway leading to 
end-stage lung disease (Li et al 2006). In the lungs of CC10:
IL-13 transgenic mice, both phosporylated p38 MAPK and 
SMAD2/3 are upregulated. Whereas p38 MAPK is activated 
in the early stage of lung disease, SMAD2/3 activation is 
seen at the end stage of the disease. This temporal separa-
tion may reﬂ  ect differing roles in the natural history of lung 
pathology, with p38 MAP kinase acting as a central mediator 
in an early inﬂ  ammatory phase, and TGFβRI kinase acting 
as a central mediator of ﬁ  rosis in a late resolution phase. 
Differentiation of these processes can be seen in our data, 
showing that p38α-selective MAPK inhibitor, SD-282 
attenuated both inﬂ  ammation and ﬁ  brosis whereas TGFβRI 
inhibitor, SD-208 selectively reduced ﬁ  brosis. The pivotal 
roles of p38α-selective MAPK inhibitor in reducing inﬂ  am-
mation and TGFβRI inhibitor in reducing ﬁ  brosis are clearly 
in agreement with our previous report proﬁ  ling the effects in 
lung ﬁ  broblasts (Kapoun et al 2006). The additional role of 
p38α-selective MAPK, SD-282 in reducing ﬁ  brosis is a novel 
ﬁ  nding and may relate to the documented cross talk between 
the p38 MAPK and TGFβRIK pathways (Martin et al 2007; 
Dziembowska et al 2007). SD-282 reduced inﬂ  ammation, 
possibly via directly inhibiting p38 MAPK activation in 
lymphocytes, and reduces hyperplasia of airway epithelium 
and goblet cell metaplasia, possibly via directly inhibiting 
p38 MAPK activation in the airway epithelial. Therefore SD-
282 indirectly reduced lung remodeling and ﬁ  brosis induced 
by chronic inﬂ  ammation. Our data are in agreement with 
observations of Ross and his colleagues (Ross et al 2006) in 
which SMAD2/3 expression is regulated by MAPK kinase-1 
in epithelial and smooth muscle cells.
In summary, we have shown in the CC10:IL-13 mouse 
model of asthma that p38α-selective MAPK inhibitor SD-282 
at a high-dose of 90 mg/kg (twice/per day, orally) given as 
therapeutic treatment at the onset of asthma for a period 
of four weeks, directly reduces inﬂ  ammation, hyperplasia 
of airway epithelium, goblet cell metaplasia, and mucus 
hypersecretion. In contrast to directly reducing ﬁ  brosis with 
TGFβRI inhibition, p38 MAPK inhibition indirectly reduces 
the lung remodeling and ﬁ  brosis and consequently alleviates 
the severity of lung damage. This study provides evidence that 
p38α-selective MAPK inhibitor may play a dual role in atten-
uating both inﬂ  ammation and ﬁ  brosis in asthma. Inhibition 
of this enzyme may be have therapeutic potential for asthma 
and other Th2-polarized inﬂ  ammatory lung diseases.
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